Controlling healthcare costs is tricky business, and sometimes the best intentions have adverse outcomes, as pointed out in a new study in the June 1st New England Journal of Medicine.
FDA Recommends Approval of Muraglitazar, But May Need To Reconsider; Which Antipsychotics Are More Dangerous?; Should CPOE Undergo Evaluation?; New Treatment for Tennis Elbow; FDA Actions
Prostate cancer is one of the leading causes of cancer in men, both in this country and in Europe. Due to the introduction of the prostate specific antigen blood test (PSA test), the ability to diagnose prostate cancer well before signs or symptoms of the disease develop has been realized. Following its introduction, the PSA was endorsed widely and recommended by many major public health organizations as a useful screening test.
Managing cardiac arrhythmias is a unique and complex challenge in the primary care setting. The clinician must balance proper initial assessment, long-term management schemes and effective acute and chronic treatment approaches with appropriate triage to a cardiac specialist and/or an electrophysiologist. The treating clinician must be able to diagnose the arrhythmia (if possible), understand the risks to the patients, and plan an acceptable therapeutic strategy. Available treatment options are evolving rapidly.
